These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 28508387)
41. Successful treatment of severe psoriasis in an adolescent with ustekinumab. AbuHilal M; Ho N Pediatr Dermatol; 2015; 32(3):377-80. PubMed ID: 25727845 [TBL] [Abstract][Full Text] [Related]
42. Predicting the unpredictable: autoantibody profile as parameter to foretell individual responses to infliximab treatment? Schön MP Br J Dermatol; 2011 Dec; 165(6):1160-1. PubMed ID: 22118556 [No Abstract] [Full Text] [Related]
43. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602 [TBL] [Abstract][Full Text] [Related]
44. Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study. Youn SW; Kim BR; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG; J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e298-e299. PubMed ID: 27976465 [No Abstract] [Full Text] [Related]
45. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus. Mazgaj M; Picard-Dahan C; Deschamps L; Marinho E; Estève E; Descamps V Int J Dermatol; 2020 Apr; 59(4):e118-e120. PubMed ID: 31957866 [No Abstract] [Full Text] [Related]
46. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report. Richetta A; Marraffa F; Grassi S; Aquila E; Dybala A; Aprile F; Merli M Australas J Dermatol; 2021 Aug; 62(3):e442-e443. PubMed ID: 33634474 [No Abstract] [Full Text] [Related]
47. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. Wang DM; Fernandez AP; Calabrese CM; Calabrese LH Clin Exp Dermatol; 2019 Jan; 44(1):113-115. PubMed ID: 29797733 [No Abstract] [Full Text] [Related]
49. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874 [TBL] [Abstract][Full Text] [Related]
50. Neutrophil-to-lymphocyte ratio decreases after treatment of psoriasis with therapeutic antibodies. Zhang L; Wiles C; Martinez LR; Han G J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):e491-e492. PubMed ID: 28502119 [No Abstract] [Full Text] [Related]
51. Inverse psoriasis treated with ustekinumab. Campos MA; Varela P; Baptista A; Moreira AI BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27222277 [TBL] [Abstract][Full Text] [Related]
52. Exacerbation of systemic lupus erythematosus in a patient with concomitant chronic plaque psoriasis treated with ustekinumab. Goh SW; Jamil A; Nor NM; Cader RA; Shaharir SS Indian J Dermatol Venereol Leprol; 2020; 86(1):68-70. PubMed ID: 31823905 [No Abstract] [Full Text] [Related]
53. Cutaneous mucinosis in a patient taking ustekinumab for palmoplantar psoriasis. Garber C; Rosmarin D; Nguyen B; Goodarzi M; Shinagare S; Jessup C; Madani A; Au SC; Hasanain A Dermatol Online J; 2017 Mar; 23(3):. PubMed ID: 28329515 [TBL] [Abstract][Full Text] [Related]
57. Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept. Brodmerkel C; Li K; Garcet S; Hayden K; Chiricozzi A; Novitskaya I; Fuentes-Duculan J; Suarez-Farinas M; Campbell K; Krueger JG J Allergy Clin Immunol; 2019 May; 143(5):1965-1969. PubMed ID: 30703387 [No Abstract] [Full Text] [Related]
58. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective. Ross C; Marshman G; Grillo M; Stanford T Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697 [TBL] [Abstract][Full Text] [Related]
59. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. Alsenaid A; Prinz JC J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):488-90. PubMed ID: 25413895 [No Abstract] [Full Text] [Related]
60. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Rouse NC; Farhangian ME; Wehausen B; Feldman SR Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):877-84. PubMed ID: 26488186 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]